A registry study of relapsed or refractory multiple myeloma pre-exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38-targeted monoclonal antibody therapy in England

Ahmed Elsada, Amy Zalin-Miller, Craig Knott, Leonidas Caravotas